

Mario Scartozzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/467829/publications.pdf>

Version: 2024-02-01

312
papers

6,729
citations

71102

41
h-index

98798

67
g-index

324
all docs

324
docs citations

324
times ranked

9539
citing authors

#	ARTICLE	IF	CITATIONS
1	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2622-2629.	1.6	402
2	Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. <i>Annals of Oncology</i> , 2009, 20, 227-230.	1.2	294
3	Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies. <i>Journal of Clinical Oncology</i> , 2004, 22, 4772-4778.	1.6	235
4	Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?. <i>Annals of Oncology</i> , 2012, 23, 2313-2318.	1.2	170
5	Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?. <i>World Journal of Gastroenterology</i> , 2018, 24, 4152-4163.	3.3	134
6	Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. <i>Lancet Oncology</i> , The, 2008, 9, 39-44.	10.7	130
7	Nuclear Factor- κ B Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 3930-3935.	1.6	121
8	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE study. <i>International Journal of Cancer</i> , 2014, 135, 1247-1256.	5.1	109
9	Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2012, 106, 799-804.	6.4	97
10	Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. <i>Oncotarget</i> , 2016, 7, 67142-67149.	1.8	91
11	Immunotherapy for colorectal cancer: where are we heading?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 709-721.	3.1	85
12	The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. <i>BMC Cancer</i> , 2014, 14, 110.	2.6	80
13	Immune Checkpoint Inhibitors in the Treatment of HCC. <i>Frontiers in Oncology</i> , 2020, 10, 601240.	2.8	77
14	Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. <i>European Journal of Cancer</i> , 2017, 86, 106-114.	2.8	76
15	Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2017, 57, 8-15.	7.7	75
16	New therapeutic targets in pancreatic cancer. <i>Cancer Treatment Reviews</i> , 2019, 81, 101926.	7.7	74
17	VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. <i>British Journal of Cancer</i> , 2013, 108, 1126-1132.	6.4	71
18	Insulin-like growth factor 1 expression correlates with clinical outcome in KRAS wild type colorectal cancer patients treated with cetuximab and irinotecan. <i>International Journal of Cancer</i> , 2010, 127, 1941-1947.	5.1	67

#	ARTICLE	IF	CITATIONS
19	Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. <i>BMC Cancer</i> , 2009, 9, 303.	2.6	66
20	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2719-2725.	1.8	66
21	Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. <i>Cancer Treatment Reviews</i> , 2004, 30, 451-459.	7.7	65
22	Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. <i>British Journal of Cancer</i> , 2011, 104, 1786-1790.	6.4	65
23	Metronomic chemotherapy from rationale to clinical studies: A dream or reality?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 46-61.	4.4	64
24	Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. <i>Gastric Cancer</i> , 2017, 20, 156-163.	5.3	62
25	High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>British Journal of Cancer</i> , 2004, 90, 1521-1525.	6.4	58
26	Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1623-1635.	3.4	58
27	Prognostic Role of Interleukin-1 β Gene and Interleukin-1 Receptor Antagonist Gene Polymorphisms in Patients With Advanced Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2339-2345.	1.6	56
28	The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment. <i>Molecules</i> , 2014, 19, 6393-6406.	3.8	56
29	The Role of HER β Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab. <i>Oncologist</i> , 2011, 16, 53-60.	3.7	55
30	5-fluorouracil pharmacogenomics: still rocking after all these years?. <i>Pharmacogenomics</i> , 2011, 12, 251-265.	1.3	54
31	Profiling Tumor-Associated Markers for Early Detection of Malignant Mesothelioma: An Epidemiologic Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 163-170.	2.5	53
32	Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer. <i>British Journal of Cancer</i> , 2015, 113, 1133-1139.	6.4	52
33	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool"™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	2.8	51
34	Immunotherapeutic approaches for hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 33897-33910.	1.8	50
35	Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options. <i>Cancer Treatment Reviews</i> , 2011, 37, 169-177.	7.7	49
36	Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. <i>Annals of Oncology</i> , 2004, 15, 489-492.	1.2	47

#	ARTICLE	IF	CITATIONS
37	The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management. PLoS ONE, 2012, 7, e32653.	2.5	47
38	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. Oncotarget, 2015, 6, 33982-33992.	1.8	46
39	Molecular classifications of gastric cancers: Novel insights and possible future applications. World Journal of Gastrointestinal Oncology, 2017, 9, 194.	2.0	46
40	Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New. BioMed Research International, 2016, 2016, 1-7.	1.9	45
41	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. Liver International, 2021, 41, 1389-1397.	3.9	45
42	EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment. International Journal of Molecular Sciences, 2022, 23, 6489.	4.1	45
43	Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Annals of Oncology, 2016, 27, 2074-2081.	1.2	44
44	Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. Journal of Translational Medicine, 2016, 14, 292.	4.4	43
45	The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. Liver International, 2020, 40, 704-711.	3.9	42
46	Chemotherapy for advanced gastric cancer: across the years for a standard of care. Expert Opinion on Pharmacotherapy, 2007, 8, 797-808.	1.8	41
47	A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF- κ B activation. British Journal of Cancer, 2008, 98, 71-76.	6.4	41
48	Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. British Journal of Cancer, 2006, 95, 445-449.	6.4	40
49	The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Oncotarget, 2015, 6, 35087-35094.	1.8	40
50	Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer. SpringerPlus, 2015, 4, 255.	1.2	40
51	Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. British Journal of Cancer, 2007, 97, 92-97.	6.4	39
52	Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. Journal of Experimental and Clinical Cancer Research, 2010, 29, 164.	8.6	39
53	Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. Lung Cancer, 2005, 49, 371-376.	2.0	36
54	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGE0 CT2BIL cohort and European multicentre validations. European Journal of Cancer, 2019, 111, 94-106.	2.8	36

#	ARTICLE	IF	CITATIONS
55	Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients. PLoS ONE, 2013, 8, e72843.	2.5	36
56	Elderly Patients with Advanced Non-Small Cell Lung Cancer. Oncology, 2003, 65, 198-203.	1.9	35
57	COX-2 and NF-KB Overexpression Is Common in Pancreatic Cancer but Does Not Predict for COX-2 Inhibitors Activity in Combination With Gemcitabine and Oxaliplatin. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 526-530.	1.3	34
58	Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan+cetuximab. Annals of Oncology, 2012, 23, 1706-1712.	1.2	34
59	Mutations of hMLH1 and hMSH2 in Patients With Suspected Hereditary Nonpolyposis Colorectal Cancer: Correlation With Microsatellite Instability and Abnormalities of Mismatch Repair Protein Expression. Journal of Clinical Oncology, 2002, 20, 1203-1208.	1.6	33
60	Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Lung Cancer, 2006, 53, 103-109.	2.0	33
61	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2014, 9, e105268.	2.5	33
62	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. Critical Reviews in Oncology/Hematology, 2017, 110, 106-116.	4.4	33
63	Clustered protocadherins methylation alterations in cancer. Clinical Epigenetics, 2019, 11, 100.	4.1	33
64	Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. Hepatology Research, 2021, 51, 1229-1241.	3.4	33
65	Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients. European Journal of Cancer, 2003, 39, 1144-1149.	2.8	32
66	Pancreatic cancer: Progress in cancer therapy. Critical Reviews in Oncology/Hematology, 2008, 67, 27-38.	4.4	32
67	The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. Expert Opinion on Investigational Drugs, 2014, 23, 925-942.	4.1	32
68	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer, 2017, 20, 825-833.	5.3	32
69	Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of interleukin-6. Haematologica, 2018, 103, e388-e391.	3.5	31
70	Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Scientific Reports, 2017, 7, 42499.	3.3	30
71	Gold Nanoparticles: A New Golden Era in Oncology?. Pharmaceuticals, 2020, 13, 192.	3.8	30
72	Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. Critical Reviews in Oncology/Hematology, 2021, 157, 103167.	4.4	30

#	ARTICLE	IF	CITATIONS
73	<i>e</i> NOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. <i>Oncotarget</i> , 2016, 7, 27988-27999.	1.8	30
74	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. <i>Oncotarget</i> , 2016, 7, 69060-69074.	1.8	29
75	Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. <i>Pancreas</i> , 2018, 47, 759-771.	1.1	29
76	Systemic therapy for the treatment of endometrial cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2019-2032.	1.8	29
77	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. <i>PLoS ONE</i> , 2020, 15, e0232449.	2.5	29
78	Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. <i>BMC Cancer</i> , 2016, 16, 429.	2.6	28
79	Multimodal treatment of resectable pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 152-165.	4.4	28
80	First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4002-4002.	1.6	28
81	Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 272-283.	4.4	27
82	Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 155-162.	3.1	27
83	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017, 22, 1463-1469.	3.7	27
84	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 115, 1-12.	4.4	26
85	Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1214.	3.7	26
86	Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. <i>Oncotarget</i> , 2016, 7, 15243-15251.	1.8	26
87	Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. <i>Annals of Oncology</i> , 2006, 17, 1661-1664.	1.2	25
88	Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. <i>Journal of Translational Medicine</i> , 2012, 10, 71.	4.4	25
89	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2016, 6, 25195.	3.3	25
90	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , 2017, 83, 106-115.	2.8	25

#	ARTICLE	IF	CITATIONS
91	Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?. <i>Oncotarget</i> , 2015, 6, 38737-38748.	1.8	25
92	New target therapies in advanced pancreatic cancer. <i>Annals of Oncology</i> , 2006, 17, v148-v152.	1.2	24
93	Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives. <i>Cancer Treatment Reviews</i> , 2009, 35, 451-462.	7.7	24
94	Colorectal Cancer Early Detection in Stool Samples Tracing CpG Islands Methylation Alterations Affecting Gene Expression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4494.	4.1	24
95	Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. , 2021, 9, e002996.		24
96	Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?. <i>European Journal of Endocrinology</i> , 2017, 177, 85-92.	3.7	23
97	Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2017, 12, 795-803.	3.6	23
98	Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 44-53.	4.4	23
99	The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. <i>Radiation Oncology</i> , 2018, 13, 83.	2.7	23
100	ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. <i>Cancers</i> , 2019, 11, 1023.	3.7	23
101	<p>Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response) Tj ETQq1 1 0.7849 14 rgBT4 Overlook		23
102	Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC). <i>Targeted Oncology</i> , 2016, 11, 489-500.	3.6	22
103	The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. <i>Scientific Reports</i> , 2016, 6, 24136.	3.3	22
104	Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. <i>Scientific Reports</i> , 2017, 7, 45703.	3.3	22
105	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. <i>Gastrointestinal Tumors</i> , 2019, 6, 92-107.	0.7	22
106	The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. <i>Cancer Treatment Reviews</i> , 2017, 53, 138-145.	7.7	20
107	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 191-199.e6.	2.3	20
108	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. <i>British Journal of Cancer</i> , 2017, 117, 315-321.	6.4	19

#	ARTICLE	IF	CITATIONS
109	BRAF-mutant colorectal cancer, a different breed evolving. Expert Review of Molecular Diagnostics, 2018, 18, 499-512.	3.1	19
110	Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. European Journal of Cancer, 2020, 133, 66-73.	2.8	19
111	The Response of Breast Cancer Cells to Mesenchymal Stem Cells. Plastic and Reconstructive Surgery, 2013, 132, 899e-910e.	1.4	18
112	Prognostic Value for Incidental Antihypertensive Therapy With β -Blockers in Metastatic Colorectal Cancer. Medicine (United States), 2015, 94, e719.	1.0	18
113	The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. Clinical Colorectal Cancer, 2017, 16, 38-43.	2.3	18
114	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The ATOREADOR Study. Clinical Colorectal Cancer, 2018, 17, e601-e615.	2.3	18
115	Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?. Lung Cancer, 2010, 68, 433-437.	2.0	17
116	Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. Pharmacogenomics, 2013, 14, 1991-1998.	1.3	17
117	Fluoropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. International Journal of Cancer, 2020, 147, 3177-3188.	5.1	17
118	The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials. Critical Reviews in Oncology/Hematology, 2022, 173, 103674.	4.4	17
119	The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer. Cancer Treatment Reviews, 2014, 40, 934-941.	7.7	16
120	Predictive and Prognostic Role of E-Cadherin Protein Expression in Patients with Advanced Gastric Carcinomas Treated with Palliative Chemotherapy. Tumor Biology, 2004, 25, 106-110.	1.8	15
121	Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. British Journal of Cancer, 2005, 92, 1051-1054.	6.4	15
122	Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer Chemotherapy and Pharmacology, 2011, 68, 37-43.	2.3	15
123	Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients. PLoS ONE, 2012, 7, e38192.	2.5	15
124	Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 113.e1-113.e7.	1.6	15
125	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Targeted Oncology, 2020, 15, 115-126.	3.6	15
126	BRCA-mutant pancreatic ductal adenocarcinoma. British Journal of Cancer, 2021, 125, 1321-1332.	6.4	15

#	ARTICLE	IF	CITATIONS
127	Health Related Quality of Life in Patients with Onco-hematological Diseases. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2020, 16, 174-179.	1.2	15
128	Elderly Patients with Advanced Colorectal Cancer: Tolerability and Activity of Chemotherapy. <i>Tumori</i> , 2005, 91, 463-466.	1.1	14
129	Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach. <i>PLoS ONE</i> , 2013, 8, e78544.	2.5	14
130	The distinctive molecular, pathological and clinical characteristics of <i>BRAF</i> -mutant colorectal tumors. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 979-987.	3.1	14
131	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. <i>Targeted Oncology</i> , 2016, 11, 593-603.	3.6	14
132	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018, 104, 476-479.	1.1	14
133	402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment. <i>Annals of Oncology</i> , 2020, 31, S412.	1.2	14
134	Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. <i>Hpb</i> , 2021, 23, 915-920.	0.3	14
135	Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 37599-37607.	1.8	14
136	Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy. <i>Current Oncology Reports</i> , 2010, 12, 175-185.	4.0	13
137	Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1872-1880.	2.3	13
138	Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , 2020, 26, 4485-4493.	7.0	13
139	Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. <i>Medicine (United States)</i> , 2020, 99, e19958.	1.0	13
140	Cholangiocarcinoma: new perspectives for new horizons. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1367-1383.	3.0	13
141	Locoregional treatments of unresectable liver metastases from colorectal cancer. <i>Cancer Treatment Reviews</i> , 1998, 24, 3-14.	7.7	12
142	Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2245-2258.	1.8	12
143	Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature. <i>Current Urology Reports</i> , 2015, 16, 3.	2.2	12
144	The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials. <i>European Journal of Cancer</i> , 2019, 111, 1-7.	2.8	12

#	ARTICLE	IF	CITATIONS
145	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 773-785.	3.6	12
146	Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. <i>ESMO Open</i> , 2021, 6, 100238.	4.5	12
147	Correlation between VEGF and VEGF-R polymorphisms, toxicity, and clinical outcome in HCC patients receiving sorafenib. <i>Journal of Clinical Oncology</i> , 2013, 31, 4123-4123.	1.6	12
148	VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. <i>Anticancer Research</i> , 2013, 33, 5017-22.	1.1	12
149	HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples. <i>British Journal of Cancer</i> , 2022, 126, 1783-1794.	6.4	12
150	Women and lung cancer: Clinical and molecular profiling as a determinate for treatment decisions. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 223-236.	4.4	11
151	Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. <i>Core Evidence</i> , 2010, 5, 61.	4.7	11
152	Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 877-885.	3.1	11
153	Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 99-106.	4.4	11
154	First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382 117, 1099-1104.	6.4	11
155	Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients?. <i>Future Oncology</i> , 2020, 16, 4337-4339.	2.4	11
156	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 865-874.	4.2	11
157	A review of immune checkpoint blockade in breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 208-225.	2.2	11
158	Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. <i>Oncotarget</i> , 2017, 8, 66699-66708.	1.8	11
159	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017, 13, 2265-2275.	2.4	10
160	Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 197-207.	1.5	10
161	Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. <i>Annals of Oncology</i> , 2011, 22, 897-902.	1.2	9
162	Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492094669.	1.3	9

#	ARTICLE	IF	CITATIONS
163	The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language?. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 332-341.	4.4	8
164	Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. <i>Frontiers in Oncology</i> , 2021, 11, 637823.	2.8	8
165	Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab. <i>Frontiers in Oncology</i> , 2021, 11, 736104.	2.8	8
166	Colorectal cancer promoter methylation alteration affects the expression of glutamate ionotropic receptor AMPA type subunit 4 alternative isoforms potentially relevant in colon tissue. <i>Human Cell</i> , 2022, 35, 310-319.	2.7	8
167	Uncovering key targets of success for immunotherapy in pancreatic cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 987-1005.	3.4	8
168	The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis. <i>Digestive and Liver Disease</i> , 2011, 43, 194-198.	0.9	7
169	Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 143-150.	1.8	7
170	No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC). <i>Scientific Reports</i> , 2016, 6, 37621.	3.3	7
171	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358.	1.1	7
172	From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. <i>Cancers</i> , 2020, 12, 1330.	3.7	7
173	The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. <i>Targeted Oncology</i> , 2021, 16, 517-527.	3.6	7
174	Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients. <i>Current Drug Targets</i> , 2014, 15, 1225-1230.	2.1	7
175	Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2467-2478.	1.8	6
176	Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. <i>Journal of Translational Medicine</i> , 2015, 13, 140.	4.4	6
177	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 591-597.	1.0	6
178	Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 82-90.e9.	2.3	6
179	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. <i>Journal of Gastrointestinal Cancer</i> , 2022, 53, 289-298.	1.3	6
180	FOLFOX4/XELOX in stage II&III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3501-3501.	1.6	6

#	ARTICLE	IF	CITATIONS
181	Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, 852583.	2.8	6
182	Molecular Biology for Stage II Colorectal Cancer: The Jury Is Still Out. <i>Journal of Clinical Oncology</i> , 2007, 25, 2861-2861.	1.6	5
183	Role of β 2 integrin in <i>HER-3</i> -negative, <i>K-RAS</i> wild-type metastatic colorectal tumors receiving cetuximab. <i>Future Oncology</i> , 2013, 9, 1207-1214.	2.4	5
184	Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. <i>OncoTargets and Therapy</i> , 2015, 8, 1149.	2.0	5
185	Metastatic gastric cancer in the last two decades: goals achieved and future promises. <i>Future Oncology</i> , 2015, 11, 2633-2636.	2.4	5
186	Hypothyroidism and Thyroid Autoimmunity as a Prognostic Biomarker of Better Response in Metastatic Cancer Long-Term Survivors Treated with Sunitinib. <i>Thyroid</i> , 2016, 26, 1336-1337.	4.5	5
187	Bone metastases in biliary cancers: A multicenter retrospective survey. <i>Journal of Bone Oncology</i> , 2018, 12, 33-37.	2.4	5
188	Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. <i>Tumori</i> , 2021, 107, 550-555.	1.1	5
189	Sequential Treatment of Sorafenib vs Regorafenib Versus Sorafenib: Physician's Choice: A Propensity Score-Matched Analysis. <i>Targeted Oncology</i> , 2021, 16, 401-410.	3.6	5
190	Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study. <i>Journal of Clinical Oncology</i> , 2022, 40, 4069-4069.	1.6	5
191	Liver metastases from colorectal cancer. <i>Annals of Oncology</i> , 1997, 8, 393-399.	1.2	4
192	The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients. <i>Oncology</i> , 2005, 68, 212-216.	1.9	4
193	Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice. <i>Expert Opinion on Therapeutic Targets</i> , 2006, 10, 281-287.	3.4	4
194	Locally Advanced Rectal Cancer Patients Receiving Radio-Chemotherapy: A Novel Clinical Pathologic Score Correlates With Global Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1437-1443.	0.8	4
195	Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. <i>Pharmacogenomics</i> , 2014, 15, 1701-1715.	1.3	4
196	Steps ahead in the treatment of advanced colorectal cancer: past, current and possible future scenarios. <i>Future Oncology</i> , 2015, 11, 2625-2628.	2.4	4
197	Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1185-1198.	4.1	4
198	Clinical impact of tumoral angiogenesis on renal cell carcinoma management: where do we stand?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 229-231.	0.7	4

#	ARTICLE	IF	CITATIONS
199	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. <i>Gastrointestinal Tumors</i> , 2019, 6, 71-80.	0.7	4
200	Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. <i>Cancer Science</i> , 2021, 112, 4819-4833.	3.9	4
201	Defining the metabolomic profile associated with early cardiotoxicity in patients with breast cancer treated with anthracyclines. <i>European Heart Journal</i> , 2020, 41, .	2.2	4
202	The Quality of Life of People with Solid Cancer is Less Worse than Other Diseases with better Prognosis, Except in the Presence of Depression. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2021, 17, 315-323.	1.2	4
203	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series. <i>European Journal of Cancer</i> , 2022, 168, 34-40.	2.8	4
204	Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib. <i>Epigenomics</i> , 2022, 14, 507-517.	2.1	4
205	Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario. <i>Vaccines</i> , 2022, 10, 679.	4.4	4
206	Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. <i>Digestive and Liver Disease</i> , 2012, 44, 74-79.	0.9	3
207	Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma. <i>Oncology Letters</i> , 2016, 12, 1415-1421.	1.8	3
208	Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report. <i>Oncology Letters</i> , 2017, 14, 2186-2190.	1.8	3
209	CALGB 80101 and the Final Call for Preoperative Chemotherapy in Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1178-1179.	1.6	3
210	Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15666-e15666.	1.6	3
211	Observational retrospective evaluation of treatment with liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic cancer patients: An Italian large real-world analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 660-660.	1.6	3
212	Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer. <i>Oncotarget</i> , 2019, 10, 2012-2021.	1.8	3
213	The Difficult Task of Diagnosing Depression in Elderly People with Cancer: A Systematic Review. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2021, 17, 295-306.	1.2	3
214	A cost-benefit analysis of chemotherapy for gastric cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2109-2114.	1.8	2
215	Liquid biopsy-driven anti-EGFR rechallenge in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3577-3577.	1.6	2
216	The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study. <i>Journal of Public Health Research</i> , 2021, 10, .	1.2	2

#	ARTICLE	IF	CITATIONS
217	A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. <i>Acta Oncologica</i> , 2021, 60, 1317-1324.	1.8	2
218	LDH serum levels as a predictive factor for global outcome in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management.. <i>Journal of Clinical Oncology</i> , 2014, 32, 497-497.	1.6	2
219	Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target. , 2009, 31, 417-23.		2
220	Response: Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1346-1347.	6.3	1
221	Chemotherapy-Free Intervals in Patients With Metastatic Colorectal Cancer: A Tale of Two Cities?. <i>Journal of Clinical Oncology</i> , 2010, 28, e268-e269.	1.6	1
222	Adenocarcinoma arising from ileoanal J-pouch mucosa. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E57-E58.	1.9	1
223	Is there an optimal choice in refractory colorectal cancer? A network meta-analysis. <i>Annals of Oncology</i> , 2019, 30, iv14.	1.2	1
224	Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study. <i>Annals of Oncology</i> , 2019, 30, v287.	1.2	1
225	Combining Immunotherapy with Anti-angiogenic Therapy: The New Standard of Care for Hepatocellular Cancer?. <i>Journal of Clinical Oncology and Therapeutics</i> , 2021, 3, .	0.1	1
226	2P Role of neutrophil-to-lymphocyte ratio (NLR) in the outcome of NSCLC EGFR mutated. <i>Journal of Thoracic Oncology</i> , 2021, 16, S699-S700.	1.1	1
227	Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. <i>Journal of Chemotherapy</i> , 2022, 34, 123-132.	1.5	1
228	440P Response to BRAF inhibitors combined with anti-EGFR after previous anti-EGFR exposure for BRAF V600E mutant metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2021, 32, S554.	1.2	1
229	417P Liquid biopsy driven anti-EGFR rechallenge in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2021, 32, S543-S544.	1.2	1
230	Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment: The CARACAS study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4051-4051.	1.6	1
231	Effect of VEGF and VEGFR polymorphisms on clinical outcome and response in patients with advanced renal cell carcinoma receiving first-line treatment.. <i>Journal of Clinical Oncology</i> , 2013, 31, 388-388.	1.6	1
232	Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5-5.	1.6	1
233	New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: apart from therapeutical protocols. <i>JOP: Journal of the Pancreas</i> , 2005, 6, 118-21.	1.5	1
234	Angiogenetic pathway as a therapeutic target in renal cell carcinoma. , 2012, 34, 15-22.		1

#	ARTICLE	IF	CITATIONS
235	The Reliability and Test-Retest Stability of the Treatment Perception Questionnaire (TPQ) in the Oncology Field: A Pilot Study. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2021, 17, 324-330.	1.2	1
236	Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. <i>Journal of Chemotherapy</i> , 2022, 34, 543-549.	1.5	1
237	Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice. <i>Tumori</i> , 2011, 97, 275-9.	1.1	1
238	Pre-operative treatment modalities in gastric cancer patients. <i>Annals of Oncology</i> , 2005, 16, iv106-iv109.	1.2	0
239	“Biliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature review” [Cancer Treatment Reviews 32(5) (2006) 333-347]. <i>Cancer Treatment Reviews</i> , 2007, 33, 497.	7.7	0
240	Aspirin and Cancer Risk. <i>JAMA Oncology</i> , 2016, 2, 1371.	7.1	0
241	Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience. <i>Annals of Oncology</i> , 2019, 30, iv81.	1.2	0
242	Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine. <i>Annals of Oncology</i> , 2019, 30, iv63.	1.2	0
243	A new prognostic score for biliary tract cancer: a multicenter experience. <i>Annals of Oncology</i> , 2019, 30, iv92.	1.2	0
244	Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study. <i>Annals of Oncology</i> , 2019, 30, iv113.	1.2	0
245	Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis. <i>Annals of Oncology</i> , 2019, 30, iv118.	1.2	0
246	Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab. <i>Annals of Oncology</i> , 2019, 30, v226.	1.2	0
247	ASSERT: A prospective, observational study measuring sodium improvement and outcomes in patients treated for moderate to severe hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Italy (lung cancer cohort). <i>Annals of Oncology</i> , 2019, 30, v742.	1.2	0
248	Sorafenib in patients with hepatocellular carcinoma: 10 years of real life. <i>Annals of Oncology</i> , 2019, 30, iv57.	1.2	0
249	Safe chemotherapy for treating early breast cancer in G6PD-deficient patients. <i>Annals of Oncology</i> , 2019, 30, iii33.	1.2	0
250	447P Long term survival with regorafenib: REALITY (real life in Italy) trial - A GISCAD Study. <i>Annals of Oncology</i> , 2020, 31, S432.	1.2	0
251	Validation and refinement of PROSASH model using the neutrophil-lymphocyte ratio in patients with HCC receiving sorafenib. <i>Liver Cancer International</i> , 2020, 1, 6-11.	1.3	0
252	3P Association between inflammation index and nutritional status and the effectiveness of immunotherapy in NSCLC treatment. <i>Annals of Oncology</i> , 2020, 31, S1418.	1.2	0

#	ARTICLE	IF	CITATIONS
253	65P Prognostic role of PECS2 index in advanced biliary tract cancer (BTC) patients treated with first line chemotherapy: Training and validation cohorts. <i>Annals of Oncology</i> , 2020, 31, S266.	1.2	0
254	767P Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammation index (SII) as prognostic factors in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis of the Italian population of the SAUL study. <i>Annals of Oncology</i> , 2020, 31, S592.	1.2	0
255	P30.02 Assessing SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion) Management and Outcome Among Lung Cancer Patients: The Assert Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, S394-S395.	1.1	0
256	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. <i>Journal of Gastrointestinal Cancer</i> , 2021, , 1.	1.3	0
257	Phase 2 study of second-line FOLFIRI-aflibercept in prospectively stratified, RAS wild type, anti-EGFR resistant, metastatic colorectal cancer patients: The DISTINCTIVE trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15503-e15503.	1.6	0
258	P-128 Influence of anti-diabetic medications on the outcomes of patients with pancreatic ductal adenocarcinoma and type 2 diabetes mellitus. <i>Annals of Oncology</i> , 2021, 32, S142.	1.2	0
259	P-129 Concomitant RAS and BRAF mutations: Impact on overall survival and progression free survival in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2021, 32, S142-S143.	1.2	0
260	Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study. <i>Clinical Colorectal Cancer</i> , 2021, , .	2.3	0
261	P-127 Lymphocyte to monocyte ratio as a prognostic factor in stage IV pancreatic ductal adenocarcinoma naive patients before gemcitabine-nab-paclitaxel chemotherapy. <i>Annals of Oncology</i> , 2021, 32, S142.	1.2	0
262	PD-5 Retrospective comparative analysis of K-ras G12C vs other K-ras mutations in metastatic colorectal cancer patients treated with first-line chemotherapy doublet + bevacizumab. <i>Annals of Oncology</i> , 2021, 32, S200.	1.2	0
263	Molecular-driven treatment for biliary tract cancer: the promising turning point. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1253-1264.	2.4	0
264	467P Monocyte to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in FOLFIRI-aflibercept treated patients: A subgroup analysis from the DISTINCTIVE trial. <i>Annals of Oncology</i> , 2021, 32, S565.	1.2	0
265	1479P Exploring second-line therapy outcome in pancreatic ductal adenocarcinoma (PDAC) patients with germlineBRCA1-2 pathogenic variants (gBRCA1-2pv). <i>Annals of Oncology</i> , 2021, 32, S1092.	1.2	0
266	459P Dynamic changes of pro-angiogenic factors during FOLFIRI-aflibercept treatment: Interim analysis of DISTINCTIVE trial. <i>Annals of Oncology</i> , 2021, 32, S562.	1.2	0
267	490P New horizons in metastatic colorectal cancer: Role of CD44 expression. <i>Annals of Oncology</i> , 2021, 32, S573-S574.	1.2	0
268	407P Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer. <i>Annals of Oncology</i> , 2021, 32, S539-S540.	1.2	0
269	A novel clinical-pathological score correlates with global outcome of locally advanced rectal cancer patients receiving neoadjuvant chemo-radiotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 3667-3667.	1.6	0
270	Palliative Treatment. , 2012, , 209-214.		0

#	ARTICLE	IF	CITATIONS
271	Adjuvant Treatment After Surgical Resection. , 2012, , 187-194.		0
272	Correlation of activated AKT and MAPK expression in liver metastases with clinical outcome in colorectal cancer patients receiving irinotecan/cetuximab treatment.. Journal of Clinical Oncology, 2012, 30, 449-449.	1.6	0
273	The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced hepatocellular carcinoma receiving sorafenib.. Journal of Clinical Oncology, 2012, 30, e14561-e14561.	1.6	0
274	Targeting Hedgehog in pancreatic cancer: An innovative approach but not for all tumors.. Journal of Clinical Oncology, 2013, 31, 205-205.	1.6	0
275	Tumor cancer stem cell genetic profile as predictor of relapse in stage II and III radically resected colon cancer patients.. Journal of Clinical Oncology, 2013, 31, 429-429.	1.6	0
276	Locally advanced or metastatic pancreatic tumors: Molecular biology may help to know it and to select the optimal treatment.. Journal of Clinical Oncology, 2013, 31, 201-201.	1.6	0
277	The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced hepatocellular carcinoma receiving sorafenib.. Journal of Clinical Oncology, 2013, 31, 208-208.	1.6	0
278	Prognostic value of incidental betablockers use in metastatic colorectal cancer patients receiving first-line treatment.. Journal of Clinical Oncology, 2013, 31, e14610-e14610.	1.6	0
279	Prognostic stratification of k-RAS wild type colorectal cancer patients receiving irinotecan-cetuximab treatment: Preliminary results of a prospective study.. Journal of Clinical Oncology, 2013, 31, 3591-3591.	1.6	0
280	Primary tumor histology and location as predictive factors for clinical outcome in metastatic gastric cancer (GC) patients receiving first-line chemotherapy.. Journal of Clinical Oncology, 2013, 31, e15081-e15081.	1.6	0
281	Antihypertensive therapy with ACE-inhibitors and clinical outcome in metastatic renal cell carcinoma (mRCC) patients.. Journal of Clinical Oncology, 2013, 31, e15536-e15536.	1.6	0
282	Angiogenesis genotyping, LDH serum levels, and treatment efficacy for advanced hepatocellular carcinoma patients receiving sorafenib.. Journal of Clinical Oncology, 2014, 32, 245-245.	1.6	0
283	Cancer stem cells profile and clinical outcome in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy.. Journal of Clinical Oncology, 2014, 32, 474-474.	1.6	0
284	Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients.. Journal of Clinical Oncology, 2014, 32, 64-64.	1.6	0
285	Correlation of distinctive angiogenetic profiles with clinical outcome for different treatment sequences in mRCC.. Journal of Clinical Oncology, 2014, 32, 474-474.	1.6	0
286	VEGF and VEGFRs polymorphisms analysis in advanced renal cell carcinoma tissues: Is heterogeneity ever the answer?. Journal of Clinical Oncology, 2014, 32, 4533-4533.	1.6	0
287	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1.. Journal of Clinical Oncology, 2014, 32, e15140-e15140.	1.6	0
288	eNOS polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib.. Journal of Clinical Oncology, 2015, 33, 230-230.	1.6	0

#	ARTICLE	IF	CITATIONS
289	Osteopontin (OPN) and interleukin-6 (IL-6) as predictive biomarkers in HCC receiving loco-regional treatment: Preliminary results.. Journal of Clinical Oncology, 2015, 33, e13501-e13501.	1.6	0
290	Multigene profiling in incidentally- and clinically detected prostate cancer.. Journal of Clinical Oncology, 2015, 33, e16107-e16107.	1.6	0
291	LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy.. Journal of Clinical Oncology, 2015, 33, e15126-e15126.	1.6	0
292	The role of sidedness, EGFR gene copy number (GCN) and EGFR promoter methylation in RAS/BRAF wild type (WT) colorectal cancer (CRC) patients receiving irinotecan/cetuximab.. Journal of Clinical Oncology, 2017, 35, 628-628.	1.6	0
293	Prognostic neutrophil-to-lymphocyte ratio in head and neck cancer: A single center experience.. Journal of Clinical Oncology, 2017, 35, e17540-e17540.	1.6	0
294	Metformin effects on clinical outcome in advanced HCC patients receiving sorafenib: Validation study.. Journal of Clinical Oncology, 2017, 35, e15684-e15684.	1.6	0
295	Prognostic value of neutrophil-to-lymphocyte ratio in advanced EGFR-mutated non-small cell lung cancer (NSCLC) treated with a tyrosine-kinase inhibitors: A retrospective analysis in a series of western patients.. Journal of Clinical Oncology, 2017, 35, e23045-e23045.	1.6	0
296	CREAM study: Clinical correlation between immunotherapy-RElated clinical outcome and intestinal microbiote in metastatic patients.. Journal of Clinical Oncology, 2018, 36, TPS215-TPS215.	1.6	0
297	Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients (Pts) with advanced biliary tract cancer (aBTC): AGE0 CT2BIL cohort update and international multicenter external validations.. Journal of Clinical Oncology, 2018, 36, e16119-e16119.	1.6	0
298	A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial.. Journal of Clinical Oncology, 2019, 37, TPS345-TPS345.	1.6	0
299	RISE-HEP project part 1: Treatment sequences evaluation in hepatocellular carcinoma cell lines.. Journal of Clinical Oncology, 2019, 37, e15663-e15663.	1.6	0
300	Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial.. Journal of Clinical Oncology, 2019, 37, TPS4151-TPS4151.	1.6	0
301	Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.. Journal of Clinical Oncology, 2019, 37, 3540-3540.	1.6	0
302	Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study.. Journal of Clinical Oncology, 2019, 37, 4075-4075.	1.6	0
303	Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer.. Journal of Clinical Oncology, 2022, 40, 182-182.	1.6	0
304	SOFT TISSUE EPITHELIOID VASCULAR TUMORS: A PRACTICAL CLINICO PATHOLOGICAL DIAGNOSTIC APPROACH. , 2021, 01, 242.		0
305	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
306	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0

#	ARTICLE	IF	CITATIONS
307	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
308	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
309	How to improve metastatic pancreatic ductal adenocarcinoma patientsâ€™ selection: Between clinical trials and the real-world. World Journal of Clinical Oncology, 2022, 13, 417-422.	2.3	0
310	From bench to bedside and back: prognostic groups of Phase 2 study of second-line FOLFIRI-aflibercept in prospectively stratified, RAS wild type, anti-EGFR resistant, metastatic colorectal cancer patients: The DISTINCTIVE trialâ€™A GISCAD study.. Journal of Clinical Oncology, 2022, 40, e15571-e15571.	1.6	0
311	Influence of type 2 diabetes mellitus and concomitant anti-diabetic medications in patients with metastatic pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, e16301-e16301.	1.6	0
312	Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy.. Journal of Clinical Oncology, 2022, 40, 4153-4153.	1.6	0